IL326135A - Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3 - Google Patents

Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3

Info

Publication number
IL326135A
IL326135A IL326135A IL32613526A IL326135A IL 326135 A IL326135 A IL 326135A IL 326135 A IL326135 A IL 326135A IL 32613526 A IL32613526 A IL 32613526A IL 326135 A IL326135 A IL 326135A
Authority
IL
Israel
Prior art keywords
steap1xcd3
methods
prostate cancer
bispecific antibodies
antibodies binding
Prior art date
Application number
IL326135A
Other languages
Hebrew (he)
Inventor
Julia Stieglmaier
Roman Kischel
Hosein Kouros-Mehr
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Julia Stieglmaier
Roman Kischel
Kouros Mehr Hosein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh, Amgen Inc, Julia Stieglmaier, Roman Kischel, Kouros Mehr Hosein filed Critical Amgen Res Munich Gmbh
Publication of IL326135A publication Critical patent/IL326135A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
IL326135A 2023-08-21 2024-08-20 Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3 IL326135A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363533824P 2023-08-21 2023-08-21
PCT/US2024/042988 WO2025042865A1 (en) 2023-08-21 2024-08-20 Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3

Publications (1)

Publication Number Publication Date
IL326135A true IL326135A (en) 2026-03-01

Family

ID=92746201

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326135A IL326135A (en) 2023-08-21 2024-08-20 Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3

Country Status (8)

Country Link
KR (1) KR20260057087A (en)
CN (1) CN121794300A (en)
AU (1) AU2024326785A1 (en)
CO (1) CO2026003434A2 (en)
IL (1) IL326135A (en)
MX (1) MX2026002085A (en)
TW (1) TW202515613A (en)
WO (1) WO2025042865A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550816A (en) * 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2007308792B2 (en) * 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MX2020008219A (en) 2018-02-08 2020-10-22 Amgen Inc Low ph pharmaceutical antibody formulation.
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
CN114929743B (en) * 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 Anti-STEAP1 antibodies and their uses

Also Published As

Publication number Publication date
KR20260057087A (en) 2026-04-27
CO2026003434A2 (en) 2026-04-06
MX2026002085A (en) 2026-04-01
TW202515613A (en) 2025-04-16
AU2024326785A1 (en) 2026-02-12
CN121794300A (en) 2026-04-03
WO2025042865A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
IL304275A (en) Methods for treating cancer
IL312680A (en) Methods for treating cancer
IL279251A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
IL276303A (en) Methods for treating cancer with anti-pd-1 antibodies
IL320332A (en) Methods for treating cancer
MX2021012767A (en) Methods of treating prostate cancer with an anti- psma/cd3 antibody.
IL299293A (en) Methods for treating cancer with combination therapies
SG11202108525VA (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
IL286337A (en) Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
IL318426A (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
CA3301695A1 (en) Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
IL308393A (en) Antibodies for treating alpha-synucleinopathies
IL307556A (en) Methods of treating cancer with anti-tigit antibodies
IL312813A (en) Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
IL325956A (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
IL320471A (en) Methods for treating dll3-expressing cancer
CA3306323A1 (en) Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors
CA3297160A1 (en) Method for treating prostate cancer
HK40087378A (en) Anti-ccr8 antibodies for treating cancer
HK40128693A (en) Methods for treating cancer using anti-ctla4 antibodies
CA3265829A1 (en) Methods for treating cancer using anti-ctla4 antibodies
HK40108797A (en) Methods for treating cancer using anti-ctla4 antibodies
GB202412414D0 (en) Methods for treating cancer
ZA202302237B (en) Prescription for treating prostate cancer
IL311380A (en) Methods for treating cancer with anti-HER2 biphasic antibodies